Third Pole Therapeutics, which is developing an inhaled nitric oxide (iNO) generator, has announced a strategic collaboration agreement with Actelion Pharmaceuticals. Details of the agreement were not specified. Third Pole's iNO platform is designed for more convenient delivery than the compressed gas cylinders currently in use. The Third Pole device is primarily … [Read more...] about Third Pole Therapeutics to collaborate with Actelion on inhaled nitric oxide development
Business
Janssen partners with Monash University on development of inhaled oxytocin
Johnson & Johnson subsidiary Janssen Pharmaceutica has announced that it signed a sponsored research agreement with Monash University's Monash Institute of Pharmaceutical Sciences (MIPS) for development of an inhaled dry powder oxytocin for the prevention and treatment of postpartum hemorrhage. No financial details were included in the announcement. According … [Read more...] about Janssen partners with Monash University on development of inhaled oxytocin
Ultibro Breezhaler and Seebri Breezhaler launched in China
According to Sosei, Novartis has launched the Ultibro Breezhaler indacaterol/glycopyrronium DPI and the Seebri Breezhaler glycopyrronium DPI in China for the treatment of COPD. Huizheng Technology acquired the Chinese licenses for the inhalers from Novartis and has filed applications to add both DPIs to the national health insurance drug list, Sosei … [Read more...] about Ultibro Breezhaler and Seebri Breezhaler launched in China
CBC Corporation partners with Iconovo on generic Symbicort
Iconovo has announced that development of a generic budesonide/formoterol DPI based on its IcoRes inhaler has been transferred to CBC Corporation. Amneal signed a development and licensing deal for the generic version of Symbicort in 2016; CBC will now assume all of Amneal's obligations under that deal. The original agreement with Amneal was described as having … [Read more...] about CBC Corporation partners with Iconovo on generic Symbicort
Altimmune announces new funding, positive results for NasoVax flu vaccine
Altimmune announced that it has raised $14 million in a registered direct offering, with net proceeds of about $12.7 million. The company also said that an extension of a Phase 2 study of its NasoVax intranasal flu vaccine found that subjects were still protected against the flu more than a year after vaccination. The company said that 8 subjects from the original … [Read more...] about Altimmune announces new funding, positive results for NasoVax flu vaccine
Endo files suit against Perrigo alleging infringement of Nascobal patents
Perrigo has announced that Endo Pharmaceuticals filed a patent suit on March 1, 2019 in the United States District Court for the District of Delaware in response to a Perrigo ANDA for a generic version of Nascobal cyanocobalamin nasal spray. Nascobal was originally approved by the FDA in 2015. The Orange Book lists 6 patents for Nascobal nasal spray, all with … [Read more...] about Endo files suit against Perrigo alleging infringement of Nascobal patents
Acorda launches Inbrija levodopa DPI in the US
Acorda Therapeutics has announced the US launch of the Inbrija levodopa dry powder inhaler in the US. In December 2018, he FDA approved Inbrija for the treatment of OFF episodes in Parkinson's disease patients taking carbidopa/levodopa. The DPI will be available to patients by prescription through certain specialty pharmacies. Acorda President and CEO Ron Cohen … [Read more...] about Acorda launches Inbrija levodopa DPI in the US
Oyster Point raises $93 million for Phase 3 development of intranasal dry eye therapies
Oyster Point Pharma said that it has raised $93 million in a Series B financing round and will use the proceeds for continued development of its OC-01 and OC-02 nicotine acetylcholine receptor (nAChR) agonist nasal sprays for the treatment of dry eye disease. In October 2018, Oyster Point announced that Phase 2b studies of each of the two nasal sprays had met … [Read more...] about Oyster Point raises $93 million for Phase 3 development of intranasal dry eye therapies
Merxin and Perlen Packaging team up to develop cannabis inhalers
Merxin Ltd and Perlen Packaging have announced that they will co-develop inhaled cannabis products based on Perlen’s BLISTair single use dry powder inhaler, with Merxin developing the formulations and marketing the cannabis DPIs. The BLISTair device is completely manufactured on a blister machine, without any molded parts, creating an inhaler from thermoformed … [Read more...] about Merxin and Perlen Packaging team up to develop cannabis inhalers
Opiant stops development of OPNT001 naloxone nasal spray for the treatment of bulimia
Opiant Pharmaceuticals said that it has discontinued development of OPNT001 naloxone nasal spray for the treatment of bulimia nervosa (BN) after a Phase 2 study failed to meet its primary endpoint. The company had announced the initiation of the study in March 2017. Opiant CEO Roger Crystal commented, “Based on these results, Opiant will not allocate further … [Read more...] about Opiant stops development of OPNT001 naloxone nasal spray for the treatment of bulimia